NEWS & PERSPECTIVES
Year:
- All
- 2024
- 2023
- 2022
- 2021
- 2020
Type:
- All
- Awards
- Kura Kommentary
- Life at Kura
- Media Coverage
Kura Kommentary
Accelerating Bio Innovation 2024
Kura Kommentary
AML World Awareness Day 2024
Media Coverage
Moving Forward, Giving Back: The ROI of Social Impact
Kura Kommentary
Kura CEO Troy Wilson on the Inflation Reduction Act
Life at Kura
Kura Core Values
Media Coverage
Kura Oncology’s CEO gives an update on Q3 earnings
Kura Kommentary
Kura Oncology 2022 Annual Report
Life at Kura
The History and Culture of Kura
Media Coverage
Navigating Dose Optimization Requirements as a Small Biotech
Media Coverage
Liquid Biopsies Guide the Development of Cancer Drugs
Life at Kura
Dr. Erba discusses the KOMET-001 Phase 1b safety and tolerability data of ziftomenib, a menin inhibitor, for patients with R/R NPM1-m AML
/in Erba, videosDr. Erba offers insight into the KOMET-007 Phase 1 trial and rationale for investigating ziftomenib in combination with standards of care for the treatment of patients with newly diagnosed or R/R NPM1-m or KMT2A-r AML
/in Erba, videosDr. Erba explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007
/in Erba, videos“Project Optimus encourages optimal biological dosing rather than maximally tolerated dosing.” — Harry Erba, MD, PhD
/in Erba, videosDr. Erba provides an overview of the KOMET clinical trial program
/in Erba, videos